Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092201839> ?p ?o ?g. }
- W2092201839 endingPage "316" @default.
- W2092201839 startingPage "311" @default.
- W2092201839 abstract "BackgroundBoth all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have proven to be very effective in obtaining high clinical complete remission (CR) rates in acute promyelocytic leukemia (APL).MethodsIn this study, 73 newly diagnosed APL subjects were treated with an ATRA and As2O3 combination treatment in remission induction and post remission therapy. Tumor burden was examined with PCR of the PML-RAR fusion transcripts, and side effects were evaluated by means of clinical examination.ResultsThe results showed that ATRA/As2O3 combination therapy yielded a CR rate of 94.5% (69/73) with a shorter time to enter CR (median: 27 days; range: 21–43 days). Four cases failed to enter CR; three of these died of cerebral hemorrhage and disseminated intravascular coagulation (DIC) within 72 hours of starting induction therapy, one older patient died of severe pulmonary infection. The early death rate was 5.5% (4/73). All 69 cases that obtained CR remained in good clinical remission after a follow-up of 35–74 months (median: 52 months).The drug toxicity profile with the use of As2O3 showed mainly hepatotoxicity. Liver dysfunction was slight in most cases. There were no severe side effects in long term follow-up.ConclusionWe conclude that APL patients may benefit from the use of the combination of ATRA and As2O3 in either remission induction or consolidation/maintenance." @default.
- W2092201839 created "2016-06-24" @default.
- W2092201839 creator A5013090646 @default.
- W2092201839 creator A5013876933 @default.
- W2092201839 creator A5014249242 @default.
- W2092201839 creator A5029425650 @default.
- W2092201839 creator A5031783487 @default.
- W2092201839 creator A5036414014 @default.
- W2092201839 creator A5049192788 @default.
- W2092201839 creator A5062736289 @default.
- W2092201839 creator A5069411879 @default.
- W2092201839 creator A5072173677 @default.
- W2092201839 creator A5074002455 @default.
- W2092201839 creator A5083527291 @default.
- W2092201839 creator A5084789064 @default.
- W2092201839 creator A5086086277 @default.
- W2092201839 creator A5088866336 @default.
- W2092201839 creator A5090156476 @default.
- W2092201839 date "2012-11-01" @default.
- W2092201839 modified "2023-10-05" @default.
- W2092201839 title "Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia" @default.
- W2092201839 cites W1515269506 @default.
- W2092201839 cites W1692919389 @default.
- W2092201839 cites W1723032639 @default.
- W2092201839 cites W1965141571 @default.
- W2092201839 cites W1980124235 @default.
- W2092201839 cites W1996909781 @default.
- W2092201839 cites W2003474867 @default.
- W2092201839 cites W2023546573 @default.
- W2092201839 cites W2029912515 @default.
- W2092201839 cites W2035586381 @default.
- W2092201839 cites W2035817692 @default.
- W2092201839 cites W2042425638 @default.
- W2092201839 cites W2043887757 @default.
- W2092201839 cites W2046705094 @default.
- W2092201839 cites W2072103198 @default.
- W2092201839 cites W2079526924 @default.
- W2092201839 cites W2095817067 @default.
- W2092201839 cites W2108362314 @default.
- W2092201839 cites W2128291738 @default.
- W2092201839 cites W2138630072 @default.
- W2092201839 cites W2143815043 @default.
- W2092201839 cites W2145371860 @default.
- W2092201839 cites W2151347057 @default.
- W2092201839 cites W2164476317 @default.
- W2092201839 cites W2170968449 @default.
- W2092201839 cites W2224360281 @default.
- W2092201839 doi "https://doi.org/10.1179/102453312x13451850327262" @default.
- W2092201839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23168069" @default.
- W2092201839 hasPublicationYear "2012" @default.
- W2092201839 type Work @default.
- W2092201839 sameAs 2092201839 @default.
- W2092201839 citedByCount "14" @default.
- W2092201839 countsByYear W20922018392012 @default.
- W2092201839 countsByYear W20922018392014 @default.
- W2092201839 countsByYear W20922018392015 @default.
- W2092201839 countsByYear W20922018392016 @default.
- W2092201839 countsByYear W20922018392017 @default.
- W2092201839 countsByYear W20922018392018 @default.
- W2092201839 countsByYear W20922018392019 @default.
- W2092201839 countsByYear W20922018392023 @default.
- W2092201839 crossrefType "journal-article" @default.
- W2092201839 hasAuthorship W2092201839A5013090646 @default.
- W2092201839 hasAuthorship W2092201839A5013876933 @default.
- W2092201839 hasAuthorship W2092201839A5014249242 @default.
- W2092201839 hasAuthorship W2092201839A5029425650 @default.
- W2092201839 hasAuthorship W2092201839A5031783487 @default.
- W2092201839 hasAuthorship W2092201839A5036414014 @default.
- W2092201839 hasAuthorship W2092201839A5049192788 @default.
- W2092201839 hasAuthorship W2092201839A5062736289 @default.
- W2092201839 hasAuthorship W2092201839A5069411879 @default.
- W2092201839 hasAuthorship W2092201839A5072173677 @default.
- W2092201839 hasAuthorship W2092201839A5074002455 @default.
- W2092201839 hasAuthorship W2092201839A5083527291 @default.
- W2092201839 hasAuthorship W2092201839A5084789064 @default.
- W2092201839 hasAuthorship W2092201839A5086086277 @default.
- W2092201839 hasAuthorship W2092201839A5088866336 @default.
- W2092201839 hasAuthorship W2092201839A5090156476 @default.
- W2092201839 hasBestOaLocation W20922018391 @default.
- W2092201839 hasConcept C104317684 @default.
- W2092201839 hasConcept C126322002 @default.
- W2092201839 hasConcept C141071460 @default.
- W2092201839 hasConcept C185592680 @default.
- W2092201839 hasConcept C190283241 @default.
- W2092201839 hasConcept C2776601000 @default.
- W2092201839 hasConcept C2776694085 @default.
- W2092201839 hasConcept C2778734968 @default.
- W2092201839 hasConcept C2780386689 @default.
- W2092201839 hasConcept C2781121885 @default.
- W2092201839 hasConcept C55493867 @default.
- W2092201839 hasConcept C71924100 @default.
- W2092201839 hasConcept C90924648 @default.
- W2092201839 hasConceptScore W2092201839C104317684 @default.
- W2092201839 hasConceptScore W2092201839C126322002 @default.
- W2092201839 hasConceptScore W2092201839C141071460 @default.
- W2092201839 hasConceptScore W2092201839C185592680 @default.
- W2092201839 hasConceptScore W2092201839C190283241 @default.
- W2092201839 hasConceptScore W2092201839C2776601000 @default.